Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Chiesi Farmaceutici S.p.A
Woman and Man Max 99 years
Chiesi Farmaceutici S.p.A
Update Il y a 4 ans
A research study to evaluate the effect of a new fixed triple combination of beclometasone dipropionate + formoterol fumarate + glycopyrronium bromide at high dose in patients with uncontrolled asthma
- To demonstrate the superiority of CHF 5993 200/6/12.5 pMDI compared to CHF 1535 200/6 pMDI in terms of change from baseline in pre-dose FEV1 at Week 26. - To demonstrate the reduction of moderate a...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Chiesi Farmaceutici S.p.A
Update Il y a 4 ans
A long-term safety trial of repeated Velmanase Alfa treatment of subjects with Alpha-Mannosidosis
The overall objective of this trial is to provide aftercare treatment with Velmanase- Alfa and to evaluate the safety and efficacy of repeated Velmanase- Alfa i.v. treatment of subjects with alpha-Man...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Chiesi Farmaceutici S.p.A
Update Il y a 4 ans
A study to evaluate the effect of a new medicine (Envarsus) compared to medicines used in current practice in new kidney transplant patients Un estudio para evaluar el efecto de un nuevo medicamento (Envarsus) en comparación con los medicamentos que se utilizan en la práctica actual en los pacientes con nuevo trasplante renal
To compare tacrolimus dosing of the new Envarsus®-based immunosuppressive regimen with current clinical practice over 6 months following de novo renal transplantation in a real-life setting in differe...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Chiesi Farmaceutici S.p.A
Update Il y a 4 ans
A research study to evaluate the effect of 3 different doses of a new medicine (glycopyrrolate) administered in combination with a licenced medicine (Foster®) in patients with uncontrolled asthma
To evaluate the efficacy of a free combination of CHF 5259 (glycopyrrolate bromide [GB]) at 3 dose levels plus Foster 100/6 µg (fixed combination of beclomethasone dipropionate [BDP] plus formoterol ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Chiesi Farmaceutici S.p.A
Update Il y a 4 ans
A phase II, multinational, multicentre, double blind, double dummy, randomised, 5-way cross-over, placebo and active controlled clinical study to test the non-inferiority of a single dose of CHF 1535 (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg dry powder) via NEXT™ DPI 1 or 4 inhalations versus CHF 1535 (beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg) pMDI with HFA-134a propellant 1 or 4 puffs on FEV1 AUC0-12h in partly controlled adult asthmatic patients
To demonstrate the non-inferiority in terms of FEV1 AUC0-12h between a single dose of CHF 1535 via NEXT™ DPI (4 inhalations of beclomethasone dipropionate + formoterol fumarate, total dose: 400 + 24 µ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Chiesi Farmaceutici S.p.A
Update Il y a 4 ans
EVALUATION OF THE EFFICACY, SAFETY AND TOLERABILITY OF THE CONCURRENT ADMINISTRATION OF CHF 4226 HFA pMDI AND EXTRAFINE BUDESONIDE HFA pMDI, BOTH GIVEN ONCE OR TWICE DAILY (2μg + 200μg qd or 1μg + 100μg bid) OVER AN 8-WEEK RANDOMIZED DOUBLE-BLIND TREATMENT PERIOD IN ADULT PATIENTS WITH MODERATE PERSISTENT ASTHMA AND PRESENTING WITH SYMPTOMS ON EXISTING INHALED CORTICOSTEROID THERAPY
Primary: To demonstrate the non inferiority in terms of morning PEF of the "free combination" of CHF 4226 HFA pMDI + extrafine budesonide HFA pMDI given once daily in the evening (2µg + 200µg qd) ve...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Chiesi Farmaceutici S.p.A
Update Il y a 4 ans
In-vivo deposition measurement of formoterol and beclomethasone after inhalation of a single dose of the combination Formoterol plus BDP HFA pMDI (Foster®, Chiesi) in healthy volunteers, asthmatic and COPD patients
The aim of the study is to assess intrapulmonary deposition of Foster.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Chiesi Farmaceutici S.p.A
Update Il y a 4 ans
A 12-week, multinational, randomised, double blind, double dummy, 4-arm parallel-group study comparing the efficacy and safety of CHF 1535 (fixed combination of beclomethasone dipropionate + formoterol fumarate) 100 + 6 μg/actuation inhalation powder, administered via the NEXT™ inhaler, versus CHF 1535 (fixed combination of beclomethasone dipropionate + formoterol fumarate) 100 + 6 μg/actuation, via HFA pressurised inhalation solution, in moderate to severe symptomatic asthmatic patients aged ≥ 12 years under treatment with inhaled corticosteroids
To demonstrate that CHF 1535 via NEXT™DPI (beclomethasone dipropionate + formoterol fumarate 100 + 6 μg), 1 inhalation or 2 inhalations twice daily, for 12 weeks is non-inferior to the corresponding d...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Chiesi Farmaceutici S.p.A
Update Il y a 4 ans
A clinical trial to investigate the comparability of relief from methacholine-induced bronchoconstriction with CHF1535 100/6 μg NEXThaler® versus CHF1535 100/6 μg pMDI in asthmatic patients
To demonstrate the non-inferiority of CHF1535 100/6 μg NEXThaler® versus CHF1535 100/6 μg pMDI on the onset of relief from methacholine-induced bronchospasm, in terms of pulmonary function [change in...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Chiesi Farmaceutici S.p.A
Update Il y a 4 ans
A study to look at the safety, tolerability and efficacy of repeated doses of different concentrations of the study drug during controlled inhalation of allergens in adult asthmatics
To determine the effect of CHF6001 DPI in attenuating the late asthmatic response (LAR) after an allergen challenge (AC) following 9 days of inhaled dosing in adult patients with allergic asthma.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
Next